Lymph node assessment and lymphadenectomy in prostate cancer

Journal of Surgical Oncology

Volumn 99, Issue 4, 2009, Pages 215-224

  Ordon, Michael ^a   Nam, Robert K ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b NONE   (Canada)

Author keywords

Lymphadenectomy; Prognosis; Prostatic neoplasm

Indexed keywords

CANCER GROWTH; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LYMPH NODE; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; METASTASIS; MORBIDITY; NOMOGRAM; PELVIS LYMPHADENECTOMY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; REVIEW;

EID: 62749113450     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21225     Document Type: Review

References (52)

1. Klein EA, Platz EA, Thompson IM. Epidemiology, Etiology and Prevention of Prostate Cancer, Campbell-Walsh Urology, 9th Edition, Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. Volume 3, Chapter 90, 2854-2857.
2. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 17 Regs Limited-Use, Nov 2006 Sub (1973-2004 varying), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission.
3. Fowler JE, Jr., Whitmore WF, Jr.: The incidence and extent of pelvic lymph node metastases in apparently localized prostatic cancer. Cancer 1981;47:2941-2945.
4. Zincke H: Extended experience with surgical treatment of stage D1 adenocarcinoma of prostate. Significant influences of immediate adjuvant hormonal treatment (orchiectomy) on outcome. Urol suppl 1989;33:27-36.
5. Stamey TA, Yang N, Hay AR, et al.: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-916.
6. Petros JA, Catalona WJ: Lower incidence of unsuspected lymph node metastases in 521 consecutive patients with clinically localized prostate cancer. J Urol 1992;147:1574-1575.
7. Han MH, Partin AW, Pound CR, et al.: Long term biochemical disease-free and cancer-specific survival following anatomical radical retropubic prostatectomy: The 15-year Johns Hopkins experience. Urol Clin North Am 2001;28:555-565.
8. Cheng L, Bergstralh EJ, Cheville JC, et al.: Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am J Surg Pathol 1998;22:1491-1500.
9. Kothari PS, Scardino PT, Ohori M, et al.: Incidence, location, and significance of periprostatic and periseminal vesicle lymph nodes in prostate cancer. Am J Surg Pathol 2001;25:1429-1432.
10. Walsh PC, Partin AW, Epstein JI: Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years. J Urol 1994;152:1831-1865.
11. Gervasi LA, Mata J, Easley JD, et al.: Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 1989;142:332-366.
12. Catalona WJ, Smith DS: Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-term results. J Urol 1998;160:2428-2434.
13. Hull GW, Rabbani F, Abbas F, et al.: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167:528-534.
14. Clark T, Parekh DJ, Cookson MS, et al.: Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 2003;169:145-148.
15. Briganti A, Chun FK, Salonia A, et al.: Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol 2006;50:1006-1013.
16. Heidenreich A, Varga Z, Von Knobloch R: Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: High incidence of lymph node metastasis. J Urol 2002;167:1681-1686.
17. Daneshmand S, Quek ML, Stein JP, et al.: Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: Long-term results. J Urol 2004;172:2252-2255.
18. Han M, Partin AW, Pound CR, et al.: Long-term biochemical disease free and cancer specific survival following anatomic radical retropubic prostatectomy: The 15 year Johns Hopkins experience. Urol Clin North Am 2001;28:555-565.
19. Allaf ME, Palapattu GS, Trock BJ, et al.: Anatomical extent of lymph node dissection: Impact on men with clinically localized prostate cancer. J Urol 2004;172:1840-1844.
20. Joslyn SA, Konety BR: Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006;68:121-125.
21. Gil-Vernet JM: Prostate cancer: Anatomical and surgical considerations. Br J Urol 1996;78:161-168.
22. Heidenreich A, Ohlmann CH, Polyakov S: Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy Eur Urol 2007;52:29-37.
23. Bhatta Dhar N, Burkhard FC, Studer UE: Role of lymphadenectomy in clinically organ-confined prostate cancer. World J Urol 2007;25:39-44.
24. Heidenreich A, von Knobloch R, Varga Z: Extended pelvic lymphadenectomy inpatients undergoing radical prostatectomy in prostate cancer: High incidence of lymph node metastases. J Urol 2001;167:1681-1684.
25. Bader P, Burkhard FC, Markwalder R, et al.: Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;169:849-854.
26. Flanigan RC, McKay TC, Olson M, et al.: Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy. Urology 1996;48:428-432.
27. Wolf JS, Jr., Cher M, Dall'era M, et al.: The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol 1995;153:993-999.
28. Borley N, Fabrin K, Sriprasad S, et al.: Laparoscopic pelvic lymph node dissection allows significantly more accurate staging in "high-risk" prostate cancer compared to MRI or CT. Scand J Urol Nephrol 2003;37:382-386.
29. de Jong IJ, Pruim J, Elsinga PH, et al.: Pre-operative staging of pelvic lymph-node in prostate cancer by 11C-choline PET. J Nucl Med 2003;44:331-335.
30. Sartor O, Mcleod D: Indium-111-capromab pendetide scans: An important test relevant to clinical decision making. Urology 2001;57:399-401.
31. Manyak MJ, Hinkle GH, Olsen JO, et al.: Immunoscintigraphy with indium-111-capromab pendetide: Evaluation before definitive therapy in patients with prostate cancer. Urology 1999;54:1058-1063.
32. Hinkle GH, Burgers JK, Neal CE, et al.: Multicenter radio- immunoscintigraphic evaluation of patients with primary prostate cancer using indium in-111 capromab pendetide. Cancer 1998;83:739-747.
33. Polascik TJ, Manyak MJ, Haseman MK, et al.: Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. Cancer 1999;85:1586-1592.
34. Ponsky LE, Cherullo EE, Starkey R, et al.: Evaluation of preoperative ProstaScint scans in the prediction of nodal disease. Prostate Cancer Prostatic Dis 2002;5:132-135.
35. Troyer JK, Beckett ML, Wright GL, Jr.: Location of prostate-specific membrane antigen in the LN CaP prostate carcinoma cell line. Prostate 1997;30:232-242.
36. Harisinghani MG, Barentsz J, Hahn PF, et al.: Noninvasive detection of clinically occult lymph node metastases in prostate cancer. N Engl J Med 2003;348:2491-2499.
37. Partin AW, Kattan MW, Subong EN, et al.: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localised prostate cancer: A multi-institutional update. JAMA 1997;147:1445-1451.
38. Partin AW, Mangold LA, Lamm DM, et al.: Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001;58:843-848.
39. Cagiannos I, Karakiewicz P, Eastham JA, et al.: A pre-operative nomogram identifying decreased risk of positive pelvic lymphnodes in patients with prostate cancer. J Urol 2003;170:1798-1803.
40. Conrad S, Graefen M, Pichlmeier U, et al.: Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma. J Urol 1998;159:2023-2029.
41. Conrad S, Graefen M, Pichlmeier U, et al.: Prospective validation of an algorithm with systematic sextant biopsy to predict pelvic lymph node metastasis in patients with clinically localized prostatic carcinoma. J Urol 2002;167:521-525.
42. Haese A, Epstein JI, Hulland H, et al.: Validation of biopsy based pathological algorithm for predicting lymph-node metastases in patients with clinically localised prostate carcinoma. Cancer 2002;95:1016-1021.
43. Briganti A, Chun FK, Salonia A, et al.: Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU Int 2006;98:788-793.
44. Briganti A, Chun FK, Salonia A, et al.: Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 2006;49:1019-1027.
45. Wawroschek F, Vogt H, Wengenmair H, et al.: Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Urol Int 2003;70:303-310.
46. Messing EM, Manola J, Yao J, et al.: Immediate hormonal therapy versus observation after radical prostatectomy and pelvic lymphadenectomy for node positive prostate cancer. Lancet Oncol 2006;7:472-479.
47. Weckermann D, Dorn R, Trefz M, et al.: Sentinel lymph node dissection for prostate cancer: Experience with more than 1,000 patients. Urol 2007;177:916-920.
48. Weingartner K, Ramaswamy A, Bittinger A, et al.: Anatomical basis for pelvic lymphadenectomy in prostate cancer: Results of an autopsy study and implications for the clinic. J Urol 1996;156:1969-1971.
49. Golimbu M, Provet J, Al-Askari S, et al.: Radical prostatectomy for stage D1 prostate cancer. Prognostic variables and results of treatment. Urology 1987;30:427-435.
50. Catalona WJ, Miller DR, Kavoussi LR: Intermediate term survival results in clinically understaged prostate cancer patients following radical prostatectomy. J Urol 1988;140:540-543.
51. Bhatta-Dar N, Reuther AM, Zippe C, et al.: No difference in six-year biochemical failure rates with or without pelvic lymphnode dissection during radical prostatectomy in low risk patients with localised prostate cancer. Urology 2004;63:528-531.
52. DiMarco DS, Zincke H, Sebo TJ, et al.: The extent of lymphadenectomy for pTXNO prostate cancer does not aVect prostate cancer outcome in the prostate specific antigen era. J Urol 2005;173:1121-1125.